You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Fotios Barkas -- 1857 2023-04-13 16:55:06 |
2 format change Peter Tang Meta information modification 1857 2023-04-14 03:34:20 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Koutsogianni, A.D.; Adamidis, P.S.; Barkas, F.; Liberopoulos, E.; Su, T.; Yamashita, S.; Liamis, G.; Rizzo, M. Familial Hypercholesterolemia and Lipoprotein(a). Encyclopedia. Available online: https://encyclopedia.pub/entry/43040 (accessed on 22 December 2025).
Koutsogianni AD, Adamidis PS, Barkas F, Liberopoulos E, Su T, Yamashita S, et al. Familial Hypercholesterolemia and Lipoprotein(a). Encyclopedia. Available at: https://encyclopedia.pub/entry/43040. Accessed December 22, 2025.
Koutsogianni, Amalia Despoina, Petros Spyridonas Adamidis, Fotios Barkas, Evangelos Liberopoulos, Ta-Chen Su, Shizuya Yamashita, George Liamis, Manfredi Rizzo. "Familial Hypercholesterolemia and Lipoprotein(a)" Encyclopedia, https://encyclopedia.pub/entry/43040 (accessed December 22, 2025).
Koutsogianni, A.D., Adamidis, P.S., Barkas, F., Liberopoulos, E., Su, T., Yamashita, S., Liamis, G., & Rizzo, M. (2023, April 13). Familial Hypercholesterolemia and Lipoprotein(a). In Encyclopedia. https://encyclopedia.pub/entry/43040
Koutsogianni, Amalia Despoina, et al. "Familial Hypercholesterolemia and Lipoprotein(a)." Encyclopedia. Web. 13 April, 2023.
Familial Hypercholesterolemia and Lipoprotein(a)
Edit
This entry is adapted from the peer-reviewed paper 10.3390/metabo12111065

Familial hypercholesterolemia (FH) is the most frequent genetic disorder resulting in increased low-density lipoprotein cholesterol (LDL-C) levels from childhood, leading to premature atherosclerotic cardiovascular disease (ASCVD) if left untreated. FH diagnosis is based on clinical criteria and/or genetic testing and its prevalence is estimated as being up to 1:300,000–400,000 for the homozygous and ~1:200–300 for the heterozygous form. Apart from its late diagnosis, FH is also undertreated, despite the available lipid-lowering therapies. In addition, elevated lipoprotein(a) (Lp(a)) (>50 mg/dL; 120 nmol/L), mostly genetically determined, has been identified as an important cardiovascular risk factor with prevalence rate of ~20% in the general population. Novel Lp(a)-lowering therapies have been developed and their cardiovascular efficacy is investigated. 

familial hypercholesterolemia lipoprotein(a) cardiovascular disease hypolipidemic treatment cholesterol

1. Introduction

Familial hypercholesterolemia (FH) is caused by mutations in the genes involved in low-density lipoprotein (LDL) catabolism, and is related to premature atherosclerotic cardiovascular disease (ASCVD) [1]. Although available lipid-lowering therapies are effective in reducing LDL-C levels and cardiovascular risk in FH patients, the majority of these are diagnosed late or remain undertreated [2]. On the other hand, elevated lipoprotein(a) (Lp(a); hyperLp(a)), controlled mostly genetically by the LPA gene locus, is also associated with increased ASCVD risk [3][4]. Novel therapies targeting apolipoprotein(a), such as antisense oligonucleotide or silent RNAs, are effective in lowering Lp(a), but their cardiovascular benefit is yet to be determined [5]. A considerable proportion of patients with FH is diagnosed with high Lp(a) levels, but there is debate about whether these two entities are associated. A few studies have demonstrated a higher prevalence of hyperLp(a) in genetically or clinically diagnosed FH patients, but others suggest that a considerable proportion of these might have been misdiagnosed due to high Lp(a) levels [6][7][8]. Nevertheless, the co-existence of FH and hyperLp(a) seems to multiply the risk of ASCVD [6].

2. Familial Hypercholesterolemia

2.1. Definition and Prevalence of FH

FH prevalence varies depending on the definition used and population studied. Homozygous patients (HoFH) are rare, with an estimated worldwide prevalence of 1:300,000–400,000 [9], while heterozygous FH (HeFH) prevalence is estimated to be ~1:200–300 [10].

2.2. Genetics of FH

FH is mostly caused by functional mutations in the following genes: LDL receptor (LDLR), proprotein convertase subtilisin kexin 9 (PCSK9), apolipoprotein B (apoB), and LDLR adaptor protein 1 (LDLRAP1) [11]. Mutations in these genes may impair the LDLR-mediated catabolism of LDL by markedly reducing hepatic LDL clearance and leading to LDL-C accumulation [11]. Among FH patients, 85–90% exhibit mutations in LDLR, 2–4% in PCSK9, 1–12% in apoB, and only a few in LDLRAP1 genes [11][12][13][14].
Considering that FH is an autosomal dominant disorder inherited with a gene-dosing effect, homozygotes are more adversely affected than heterozygotes [9]. It should also be noted that most HoFH patients are compound heterozygotes [9]. This is attributed to a large number of distinct LDLR gene mutations [9]. Therefore, an adult with HoFH is more likely to have inherited genetic mutations in two different LDLRs [9]. True homozygosity more often occurs in cases of consanguineous union between two heterozygotes [9]. Of note, a high prevalence of a limited number of LDLR mutations may occur in a region due to the founder gene effect [9].

2.3. Clinical Presentation of FH

If left untreated, males and females with HeFH typically develop coronary heart disease (CHD) before the age of 55 and 60, respectively, while HoFH individuals develop CHD very early in life, and many will die before the age of 20 [15][16].
The characteristic lipid profile of FH patients consists of elevated total cholesterol and LDL-C (usually ≥190 mg/dL for HeFH or ≥500 mg/dL for HoFH) with normal high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels [15][16].

2.4. Diagnosis of FH

The diagnosis of HeFH is based on genetic testing or clinical criteria [17][18]. The most commonly used clinical criteria for HeFH are the Dutch Lipid Clinic Network (DLCN) which include patient family history for increased LDL-C levels, personal clinical history of premature ASCVD, the presence of tendon xanthomas, the presence of corneal arcus in a person < 45 years, patient LDL-C levels, and genetic testing, if available [13]. HoFH diagnosis is based on either genetic testing or an untreated/treated LDL-C > 500/300 mg/dL together with the presence of xanthomas before the age of 10 years or untreated LDL-C levels in both parents compatible with HeFH [13].
In the case of FH diagnosis, a screening cascade in all first-degree relatives is strongly recommended, including children beginning from the age of 2 years [10]. It is worth mentioning that, despite its well-documented high prevalence, <5% of those with FH have been diagnosed worldwide and the majority of those are diagnosed over 40 years old [2].

2.5. Prognosis and Treatment of FH

At any level of untreated LDL-C, the prognosis for HeFH patients is worse than individuals without FH [19]
Possible ASCVD predictors in FH patients include family ASCVD history, age, gender, smoking, hypertension, type 2 diabetes, hyperLp(a), as well as other potential risk modifiers [1]. These include genetic parameters beyond the traditional FH-causing mutations, parameters of HDL composition and function, inflammation, telomere length in somatic cells, oxidative stress, and hemostasis [1].
Concerning FH treatment, the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) 2019 guidelines recommend an LDL-C target < 70 mg/dL (1.8 mmol/L) for FH patients without cardiovascular risk factors, and <55 mg/dL (1.4 mmol/L) for those with ASCVD or additional risk factors [10].
Maximally tolerated statin therapy ± ezetimibe is the cornerstone of treatment for FH patients [20]. Other therapeutic agents include PCSK9 inhibitors, bempedoic acid, and bile acid sequestrants [20][21]. In the case of HoFH, lomitapide, evinacumab, and lipoprotein apheresis are additional treatment options [20].

3. Lipoprotein(a)

3.1. Molecular Properties of Lp(a)

Lp(a) consists of an LDL-like particle, in which apoB-100 is linked by a single disulfide bridge to a unique plasminogen-like glycoprotein, known as apolipoprotein(a) (apo(a)) [3][4]. The LDL-like core constitutes a combination of triacylglycerols, phospholipids, and esterified/unesterified cholesterol surrounded by one molecule of apoB-100 [3][4]. Considering its formation, Lp(a) contributes to atherosclerosis, but also exerts inflammatory, oxidative, thrombotic, and antifibrinolytic properties [3][22][23].

3.2. Genetics of Lp(a)

About 90% of the Lp(a) level is autosomal dominantly inherited and strongly determined by a single gene, the LPA gene [23]. Most individuals express two distinct Lp(a) isoforms [23]. The LPA gene, located in chromosome 6q23, is evolutionarily derived from the plasminogen (PLG) gene and remains highly homologous to it [23][24][25][26]. The LPA gene, and thus apo(a), consists of two kringle domains: kringle V (KV) and kringle IV (KIV) [23][27]. KV is similar in apo(a) and plasminogen [23][27]. Although KIV is present only once in plasminogen, it is expressed in 10 different types in apo(a) [23][27]. Specifically, KIV contains one copy of KIV1 and KIV3–10, but variable copies of KIV2 (1 to >40 on each allele) [23][27]. KIV2 and its different repeats in apo(a) account for the high size apo(a) polymorphism and determine the size of each apo(a) isoform, its formation rate, and serum Lp(a) concentrations [26][27].

3.3. Definition and Prevalence of High Lp(a)

Plasma Lp(a) levels vary widely between individuals and are largely determined by apo(a) size [28]. There is an inverse relationship between the number of KIV2 repeats of apo(a) and Lp(a) levels in plasma [29]. Consequently, small apo(a) isoforms are related to hyperLp(a) [29]. The presence of the LPA single-nucleotide polymorphisms rs3798220 and rs10455872 is also associated with hyperLp(a) [30][31]. Lp(a) levels double over the first year of life in parallel with the apo(a) gene, which is fully expressed from the first or second year of life [32][33]. Afterwards, Lp(a) levels are stable over time and seem not to be affected by diet, physical activity, or other environmental factors [3][34]. Thus, Lp(a) is enough to be measured once, unless a secondary cause is suspected or specific treatment is instituted [3][34].
Lp(a) measurement is challenging in clinical practice [35]. There is substantial variability in assays, partly due to apo(a) structure and variability in K-IV repeats [35]. Ideally, clinical assays should use an antibody for a unique non-repetitive epitope in apo(a), to recognize each Lp(a) particle once and report levels as nmol/L [35]. On the other hand, Lp(a) values measured by assays based on polyclonal antibodies cannot be reported in molar units [35]. As a compromise, they approximate their findings by comparison with apo(a) isoform-insensitive reference methods that use molar units; in case this is impossible, Lp(a) values should be reported in mg/dL [35].
Traditional thresholds for hyperLp(a) are >30 mg/dL (>75 nmol/L), with about 20% of the general population having Lp(a) >50 mg/dL (>120 nmol/L) [3][35][36].
The cholesterol contained in Lp(a) particles cannot be separated from that in LDL particles and is thus totally reported as LDL-C concentration [35]. The analyses of isolated Lp(a) particles have shown so far that cholesterol accounts for 30–45% of Lp(a) mass concentration [35]. Therefore, it has been suggested that Lp(a)-cholesterol (Lp(a)-C) can be estimated by multiplying the Lp(a) mass by 0.3, whereas corrected LDL-C is equal to measured LDL-C minus Lp(a)-C [35]. However, this approach has limitations [35]. The direct measurement of Lp(a)-C relative to Lp(a) mass has shown inter- and intraindividual variation ranging from 6% to 60%, which may affect the prediction risk [35]. Therefore, the routine correction of LDL-C for Lp(a)-C is not strongly recommended [35].

3.4. Clinical Presentation of hyperLp(a)

The physiological role of Lp(a) is not thoroughly understood. Evidence from experimental, observational, and genetic studies has demonstrated that hyperLp(a) is an established risk factor for CHD, ischemic stroke, peripheral artery disease, heart failure, calcific aortic valve stenosis, and retinopathy in diabetic patients [3][34][35][37][38][39][40][41].
Recent guidelines recommend that Lp(a) levels should be measured at least once in each adult’s lifetime to identify those with hyperLp(a) [10]. Moreover, Lp(a) measurement should be considered in patients with personal or family history of premature ASCVD, and family history of high Lp(a) or FH [10][35]; premature atherosclerosis can be easily detected by endothelial dysfunction and early carotid lesions [42]. Screening for Lp(a) is also recommended in youth with a history of ischemic stroke and no other identifiable risk factors [35].

3.5. Available and Upcoming Therapies for hyperLp(a)

There are neither known nonpharmacologic methods nor any medications specifically approved for lowering Lp(a) levels [23]. However, some currently used therapeutic agents have a limited effect on Lp(a) [23]. Although low-saturated fat diets and statin therapy have been previously considered to raise Lp(a) levels by approximately 10–30% [4][23][43][44][45][46] a secondary analysis of the Familial Hypercholesterolemia Expert Forum (FAME) study including a Japanese nationwide cohort of FH patients has recently shown opposing results [47]. According to this analysis, the Lp(a) levels tended to lower in those under treatment (n = 399) after 2–4 years of follow-up compared with the baseline values [47].
On the other hand, lipoprotein apheresis is highly effective in reducing Lp(a) levels (25–40%) [4][23]. Similarly, fibrates, niacin, lomitapide, PCSK9 and cholesteryl transfer protein (CETP) inhibitors, aspirin, antibodies to interleukin-6, nutraceuticals, tibolone, and ezetimibe moderately decrease Lp(a) levels [4][23][48].
Novel medicines based on antisense oligonucleotides (ASOs) and small interfering RNAs (siRNA) technology are currently in clinical development [4][23][49][50]. Pelacarsen, an ASO, has shown much promise with reductions of up to 92.4% in Lp(a), olpasiran, a siRNA, reduced Lp(a) with observed maximal percent reductions of >90% in a phase I study, whereas the siRNA SLN360 also reduced plasma Lp(a) concentrations in a dose-dependent way [4][23][49][50].

References

  1. Bianconi, V.; Banach, M.; Pirro, M. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc. Med. 2021, 31, 205–215.
  2. Vallejo-Vaz, A.J.; Stevens, C.A.; Lyons, A.R.; Dharmayat, K.I.; Freiberger, T.; Hovingh, G.K.; Mata, P.; Raal, F.J.; Santos, R.D.; Soran, H.; et al. Global perspective of familial hypercholesterolaemia: A cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet 2021, 398, 1713–1725.
  3. Gencer, B.; Kronenberg, F.; Stroes, E.S.; Mach, F. Lipoprotein(a): The revenant. Eur. Heart J. 2017, 38, 1553–1560.
  4. Koutsogianni, A.-D.; Liberopoulos, E.; Tselepis, A.D. Lipoprotein(a): An update on its role in human health and disease. J. Atheroscler. Prev. Treat. 2021, 12, 92–102.
  5. Nordestgaard, B.G.; Chapman, M.J.; Ray, K.; Borén, J.; Andreotti, F.; Watts, G.; Ginsberg, H.; Amarenco, P.; Catapano, A.L.; Descamps, O.S.; et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur. Heart J. 2010, 31, 2844–2853.
  6. Alonso, R.; Andres, E.; Mata, N.; Fuentes-Jiménez, F.; Badimón, L.; López-Miranda, J.; Padró, T.; Muñiz, O.; Díaz-Díaz, J.L.; Mauri, M.; et al. Lipoprotein(a) Levels in Familial Hypercholesterolemia: An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation. J. Am. Coll. Cardiol. 2014, 63, 1982–1989.
  7. Langsted, A.; Kamstrup, P.R.; Benn, M.; Tybjærg-Hansen, A.; Nordestgaard, B.G. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: A prospective cohort study. Lancet Diabetes Endocrinol. 2016, 4, 577–587.
  8. Trinder, M.; DeCastro, M.L.; Azizi, H.; Cermakova, L.; Jackson, L.M.; Frohlich, J.; Mancini, G.J.; Francis, G.A.; Brunham, L.R. Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. J. Am. Coll. Cardiol. 2020, 75, 2682–2693.
  9. Sjouke, B.; Kusters, D.M.; Kindt, I.; Besseling, J.; Defesche, J.C.; Sijbrands, E.J.; van Lennep, J.E.R.; Stalenhoef, A.F.; Wiegman, A.; de Graaf, J.; et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: Prevalence, genotype–phenotype relationship, and clinical outcome. Eur. Heart J. 2015, 36, 560–565.
  10. Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2020, 41, 111–188.
  11. Austin, M.A.; Hutter, C.M.; Zimmern, R.L.; Humphries, S.E. Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review. Am. J. Epidemiol. 2004, 160, 407–420.
  12. Futema, M.; Whittall, R.A.; Kiley, A.; Steel, L.K.; Cooper, J.A.; Badmus, E.; Leigh, S.E.; Karpe, F.; Neil, H.A.W.; Humphries, S.E. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis 2013, 229, 161–168.
  13. Goldberg, A.C.; Hopkins, P.N.; Toth, P.P.; Ballantyne, C.M.; Rader, D.J.; Robinson, J.G.; Daniels, S.R.; Gidding, S.S.; de Ferranti, S.D.; Ito, M.K.; et al. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 2011, 5, S1–S8.
  14. Santos, R.D.; Gidding, S.S.; Hegele, R.A.; Cuchel, M.A.; Barter, P.J.; Watts, G.F.; Baum, S.J.; Catapano, A.L.; Chapman, M.J.; Defesche, J.C.; et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: A consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016, 4, 850–861.
  15. Austin, M.A.; Hutter, C.M.; Zimmern, R.L.; Humphries, S.E. Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review. Am. J. Epidemiol. 2004, 160, 421–429.
  16. Hutter, C.M.; Austin, M.A.; Humphries, S.E. Familial Hypercholesterolemia, Peripheral Arterial Disease, and Stroke: A HuGE Minireview. Am. J. Epidemiol. 2004, 160, 430–435.
  17. Benn, M.; Watts, G.F.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Mutations causative of familial hypercholesterolaemia: Screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur. Heart J. 2016, 37, 1384–1394.
  18. Stone, N.J.; Robinson, J.G.; Lichtenstein, A.H.; Merz, C.N.B.; Blum, C.B.; Eckel, R.H.; Goldberg, A.C.; Gordon, D.; Levy, D.; Lloyd-Jones, D.M.; et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2014, 63, 2889–2934.
  19. Khera, A.V.; Won, H.-H.; Peloso, G.M.; Lawson, K.S.; Bartz, T.M.; Deng, X.; van Leeuwen, E.M.; Natarajan, P.; Emdin, C.A.; Bick, A.G.; et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J. Am. Coll. Cardiol. 2016, 67, 2578–2589.
  20. Rizos, C.V.; Skoumas, I.; Rallidis, L.; Skalidis, E.; Tziomalos, K.; Garoufi, A.; Anagnostis, P.; Sfikas, G.; Kotsis, V.; Doumas, M.; et al. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. Int. J. Cardiol. 2021, 345, 119–124.
  21. Banach, M.; Rizzo, M.; Obradovic, M.; Montalto, G.; Rysz, J.; Mikhailidis, D.P.; Isenovic, E.R. PCSK9 inhibition-a novel mechanism to treat lipid disorders? Curr. Pharm. Des. 2013, 19, 3869–3877.
  22. Tsimikas, S.; Karwatowska-Prokopczuk, E.; Gouni-Berthold, I.; Tardif, J.C.; Baum, S.J.; Steinhagen-Thiessen, E.; Shapiro, M.D.; Stroes, E.S.; Moriarty, P.M.; Nordestgaard, B.G.; et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N. Engl. J. Med. 2020, 382, 244–255.
  23. Jawi, M.M.; Frohlich, J.; Chan, S.Y. Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. J. Lipids 2020, 2020, 3491764.
  24. Tsimikas, S.A. Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J. Am. Coll. Cardiol. 2017, 69, 692–711.
  25. Ellis, K.L.; Boffa, M.B.; Sahebkar, A.; Koschinsky, M.L.; Watts, G.F. The renaissance of lipoprotein(a): Brave new world for preventive cardiology? Prog. Lipid Res. 2017, 68, 57–82.
  26. Cai, A.; Li, L.; Zhang, Y.; Mo, Y.; Mai, W.; Zhou, Y. Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment. Dis. Markers 2013, 35, 551–559.
  27. Saleheen, D.; Haycock, P.C.; Zhao, W.; Rasheed, A.; Taleb, A.; Imran, A.; Abbas, S.; Majeed, F.; Akhtar, S.; Qamar, N.; et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: A mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017, 5, 524–533.
  28. Hobbs, H.H.; White, A.L. Lipoprotein(a): Intrigues and Insights: Current Opinion in Lipidology. Curr. Opin. Lipidol. 1999, 10, 225–236. Available online: https://journals.lww.com/co-lipidology/Abstract/1999/06000/Lipoprotein_a___intrigues_and_insights.5.aspx (accessed on 21 December 2021).
  29. Rader, D.J.; Cain, W.; Ikewaki, K.; Talley, G.; Zech, L.A.; Usher, D.; Brewer, H.B. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J. Clin. Investig. 1994, 93, 2758–2763.
  30. Arai, K.; Luke, M.M.; Koschinsky, M.L.; Miller, E.R.; Pullinger, C.R.; Witztum, J.L.; Kane, J.P.; Tsimikas, S. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis 2010, 209, 498–503.
  31. Rao, F.; Schork, A.J.; Maihofer, A.X.; Nievergelt, C.M.; Marcovina, S.M.; Miller, E.R.; Witztum, J.L.; O’Connor, D.T.; Tsimikas, S. Heritability of Biomarkers of Oxidized Lipoproteins: A Twin Pair Study. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 1704–1711.
  32. Wang, X.L.; Wilcken, D.E.L.; Dudman, N.P.B. Early expression of the apolipoprotein (a) gene: Relationships between infants’ and their parents’ serum apolipoprotein (a) levels. Pediatrics 1992, 89, 401–406.
  33. Rifai, N.; Heiss, G.; Doetsch, K. Lipoprotein(a) at birth, in blacks and whites. Atherosclerosis 1992, 92, 123–129.
  34. Cegla, J.; Neely, R.G.; France, M.; Ferns, G.; Byrne, C.D.; Halcox, J.; Datta, D.; Capps, N.; Shoulders, C.; Qureshi, N.; et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis 2019, 291, 62–70.
  35. Kronenberg, F.; Mora, S.; Stroes, E.S.G.; Ference, B.A.; Arsenault, B.J.; Berglund, L.; Dweck, M.R.; Koschinsky, M.; Lambert, G.; Mach, F.; et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur. Heart J. 2022, 43, 3925–3946.
  36. Tsimikas, S.; Fazio, S.; Ferdinand, K.C.; Ginsberg, H.N.; Koschinsky, M.L.; Marcovina, S.M.; Moriarty, P.M.; Rader, D.J.; Remaley, A.T.; Reyes-Soffer, G.; et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J. Am. Coll. Cardiol. 2018, 71, 177–192.
  37. Gencer, B.; Mach, F. Lipoprotein(a): The perpetual supporting actor. Eur. Heart J. 2018, 39, 2597–2599.
  38. Malaguarnera, G.; Gagliano, C.; Bucolo, C.; Vacante, M.; Salomone, S.; Malaguarnera, M.; Leonardi, D.G.; Motta, M.; Drago, F.; Avitabile, T. Lipoprotein(a) serum levels in diabetic patients with retinopathy. BioMed Res. Int. 2013, 2013, 943505.
  39. Arnold, M.; Schweizer, J.; Nakas, C.T.; Schütz, V.; Westphal, L.P.; Inauen, C.; Pokorny, T.; Luft, A.; Leichtle, A.; Arnold, M.; et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: Results from the BIOSIGNAL study. Eur. Heart J. 2021, 42, 2186–2196.
  40. Koutsogianni, A.D.; Liberopoulos, E.; Tellis, K.; Tselepis, A.D. Oxidized phospholipids and lipoprotein(a): An update. Eur. J. Clin. Investig. 2021, 52, e13710.
  41. Nordestgaard, B.G.; Langsted, A. Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. J. Lipid Res. 2016, 57, 1953–1975.
  42. Corrado, E.; Rizzo, M.; Coppola, G.; Muratori, I.; Carella, M.; Novo, S. Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: A 24-month follow-up study. Coron. Artery Dis. 2008, 19, 139–144.
  43. Takagi, H.; Umemoto, T. Atorvastatin decreases lipoprotein(a): A meta-analysis of randomized trials. Int. J. Cardiol. 2012, 154, 183–186.
  44. Fraley, A.E.; Schwartz, G.G.; Olsson, A.G.; Kinlay, S.; Szarek, M.; Rifai, N.; Libby, P.; Ganz, P.; Witztum, J.L.; Tsimikas, S. Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes: Results From the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) Trial. J. Am. Coll. Cardiol. 2009, 53, 2186–2196.
  45. Khera, A.V.; Everett, B.M.; Caulfield, M.P.; Hantash, F.M.; Wohlgemuth, J.; Ridker, P.M.; Mora, S. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial. Circulation 2014, 129, 635–642.
  46. Arsenault, B.J.; Barter, P.; Demicco, D.A.; Bao, W.; Preston, G.M.; LaRosa, J.C.; Grundy, S.M.; Deedwania, P.; Greten, H.; Wenger, N.K.; et al. Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers. PLoS ONE 2014, 9, e114519.
  47. Naito, R.; Daida, H.; Masuda, D.; Harada-Shiba, M.; Arai, H.; Bujo, H.; Ishibashi, S.; Koga, N.; Oikawa, S.; Yamashita, S. Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J. Atheroscler. Thromb. 2022, 29, 1188–1200.
  48. Fogacci, F.; Banach, M.; Mikhailidis, D.P.; Bruckert, E.; Toth, P.P.; Watts, G.F.; Reiner, Ž.; Mancini, J.; Rizzo, M.; Mitchenko, O.; et al. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 2019, 143, 1–16.
  49. Nissen, S.E.; Wolski, K.; Balog, C.; Swerdlow, D.I.; Scrimgeour, A.C.; Rambaran, C.; Wilson, R.J.; Boyce, M.; Ray, K.K.; Cho, L.; et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA 2022, 327, 1679–1687.
  50. Koren, M.J.; Moriarty, P.M.; Baum, S.J.; Neutel, J.; Hernandez-Illas, M.; Weintraub, H.S.; Florio, M.; Kassahun, H.; Melquist, S.; Varrieur, T.; et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat. Med. 2022, 28, 96–103.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cardiac & Cardiovascular Systems
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Amalia Despoina Koutsogianni ,
Petros Spyridonas Adamidis
, Fotios Barkas , Evangelos Liberopoulos , Ta-Chen Su , Shizuya Yamashita , George Liamis , Manfredi Rizzo
View Times: 485
Revisions: 2 times (View History)
Update Date: 14 Apr 2023
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback